Pfizer COVID-19 vaccine effectiveness drops 6 months after 2nd measure: s…

The effectiveness of the Pfizer Inc/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second measure, according to data published on Monday that U.S. health agencies considered when deciding on the need for booster shots.

The data, which was published in the Lancet medical journal, had been before released in August ahead of peer review.

Read more:
Pfizer launches large study of oral COVID-19 prevention drug

The examination showed that the vaccine’s effectiveness in preventing hospitalization and death remained high at 90% for at the minimum six months, already against the highly contagious Delta variant of the coronavirus.

The data indicates that the drop is due to waning efficacy, instead of more contagious variants, researchers said.

Story continues below advertisement

Researchers from Pfizer and Kaiser Permanente studied electronic health records of approximately 3.4 million people who were members of Kaiser Permanente Southern California between December 2020 – when the vaccine first became obtainable – and August of 2021.

“Our variant-specific examination clearly shows that the (Pfizer/BioNTech) vaccine is effective against all current variants of concern, including Delta,” said Luis Jodar, senior vice president and chief medical officer at Pfizer vaccines.

Why your flu shot could be already more important this year

Why your flu shot could be already more important this year

A possible limitation of the study was a without of data on adherence to masking guidelines and occupations in the study population, which could have affected frequency of testing and likelihood of exposure to the virus.

Vaccine effectiveness against the Delta variant was 93% after the first month, declining to 53% after four months. Against other coronavirus variants, efficacy declined to 67% from 97%.

Story continues below advertisement

Read more:
The booster argue: Will you need a third COVID-19 shot?

“To us, that indicates Delta is not an escape variant that is completely evading vaccine protection,” said study leader Sara Tartof with Kaiser Permanente Southern California’s Department of Research & Evaluation.

“If it was, we would probably not have seen high protection after vaccination, because vaccination would not be working in that case. It would start low, and stay low.”

Testing for variants is more likely to fail in vaccinated individuals, which could rule to overestimation of variant-specific effectiveness in the study, the authors warned.

The U.S. Food and Drug Administration has empowered the use of a booster measure of the Pfizer/BioNTech vaccine for older adults and some Americans at high-risk of getting infected. Scientists have called for more data on whether boosters should be recommended for all.

Should we be concerned about ‘waning immunity’?

Should we be concerned about ‘waning immunity’? – Sep 25, 2021

(Reporting by Manas Mishra in Bengaluru; Editing by Bill Berkrot)

View link »

Click: See details

Leave a Reply